NEW YORK, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Alcobra Ltd. ("Alcobra" or the "Company") (Nasdaq:ADHD) securities between March 28, 2014 and November 14, 2014.
For more information, click here: http://zlk.9nl.com/alcobra-adhd.
The complaint alleges that Alcobra failed to disclose during the Class Period that, despite statements to the contrary, its drug MDX did not show a statistical benefit over placebo unless certain patients were removed from the Company's analysis of the Phase III study such that the Company presented its analyses inconsistent with and outside the original protocols.
On October 22, 2014, Alcobra announced that the MDX Phase III study, in fact, did not demonstrate a statistically significant improvement in patient symptoms. Then on November 17, 2014, the Company announced that it would meet with the FDA to launch a second adult Phase III study next year.
If you suffered a loss in Alcobra you have until January 19, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/alcobra-adhd.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com
